Department of Pharmacology and Chemical Biology, University of Pittsburgh, USA; Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, USA.
Department of Health Services, University of Washington, USA.
Redox Biol. 2020 May;32:101463. doi: 10.1016/j.redox.2020.101463. Epub 2020 Feb 14.
Brain and heart injury cause most out-of-hospital cardiac arrest deaths but limited pharmacotherapy exists to protect these tissues. Nitrite is a nitric oxide precursor that is protective in pre-clinical models of ischemic injury and safe in Phase I testing. Protection may occur by cGMP generation via the sGC pathway or through S-nitrosothiol and nitrated conjugated linoleic acid (NO-CLA) formation. We hypothesized that nitrite provided during CPR signals through multiple pathways and that activation of signals is associated with OHCA outcome. To this end, we performed a secondary analysis of a phase 1 study of intravenous nitrite administration during resuscitation in adult out-of-hospital cardiac arrest. Associations between whole blood nitrite and derived plasma signals (cGMP and NO-CLA) with patient characteristics and outcomes were defined using Chi-square or t-tests and multiple logistic regression. Whole blood nitrite levels correlated inversely with plasma NO-CLA (p = 0.039) but not with cGMP. Patients with shockable rhythms had higher cGMP (p = 0.027), NO-CLA (p < 0.0001) and trended towards lower nitrite (p = 0.077). Importantly, plasma cGMP and NO-CLA levels were higher in survivors (p = 0.033 and 0.019) and in those with good neurological outcome (p = 0.046 and 0.021). Nitrite was lower in patients with good neurologic outcome (p = 0.029). cGMP (OR 4.02; 95% CI 1.04-15.54; p = 0.044) and NO-CLA (OR 3.74; 95% CI 1.11-12.65; p = 0.034) were associated with survival. Nitrite (OR 0.20; 95% CI 0.05-0.08; p = 0.026) and NO-CLA (OR 3.96; 95% CI 1.01-15.60; p = 0.049) were associated with favorable neurologic outcome. In summary, nitrite administration was associated with increased plasma cGMP and NO-CLA formation in selected OHCA patients. Furthermore, patients with the highest levels of cGMP and NO-CLA were more likely to survive and experience better neurological outcomes.
脑和心脏损伤是导致院外心脏骤停死亡的主要原因,但目前用于保护这些组织的药物治疗方法有限。亚硝酸盐是一种一氧化氮前体,在缺血性损伤的临床前模型中具有保护作用,并且在 I 期试验中是安全的。这种保护可能是通过 sGC 途径产生 cGMP 或通过 S- 亚硝硫醇和硝化共轭亚油酸(NO-CLA)的形成来实现的。我们假设亚硝酸盐在 CPR 期间通过多种途径发出信号,并且信号的激活与 OHCA 结果相关。为此,我们对一项在成人院外心脏骤停复苏期间静脉内给予亚硝酸盐的 I 期研究进行了二次分析。使用卡方检验或 t 检验和多元逻辑回归定义全血亚硝酸盐与衍生的血浆信号(cGMP 和 NO-CLA)与患者特征和结局之间的关联。全血亚硝酸盐水平与血浆 NO-CLA 呈负相关(p = 0.039),但与 cGMP 无关。有可除颤节律的患者的 cGMP 更高(p = 0.027),NO-CLA 更高(p < 0.0001),亚硝酸盐水平有下降趋势(p = 0.077)。重要的是,幸存者的血浆 cGMP 和 NO-CLA 水平更高(p = 0.033 和 0.019),神经功能良好的患者的水平更高(p = 0.046 和 0.021)。神经功能良好的患者的亚硝酸盐水平更低(p = 0.029)。cGMP(OR 4.02;95%CI 1.04-15.54;p = 0.044)和 NO-CLA(OR 3.74;95%CI 1.11-12.65;p = 0.034)与存活相关。亚硝酸盐(OR 0.20;95%CI 0.05-0.08;p = 0.026)和 NO-CLA(OR 3.96;95%CI 1.01-15.60;p = 0.049)与良好的神经功能结局相关。总之,在选定的 OHCA 患者中,亚硝酸盐的给予与血浆 cGMP 和 NO-CLA 形成的增加有关。此外,具有最高 cGMP 和 NO-CLA 水平的患者更有可能存活并获得更好的神经功能结局。